Research programme: klotho gene therapy - Klogene Therapeutics

Drug Profile

Research programme: klotho gene therapy - Klogene Therapeutics

Alternative Names: alpha Klotho gene therapy; s-KL gene therapy

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Universitat Autonoma de Barcelona; Vall d-Hebron Research Institute
  • Developer Klogene Therapeutics; Universitat Autonoma de Barcelona; Vall d-Hebron Research Institute
  • Class Antidementias; Gene therapies
  • Mechanism of Action Klotho-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia; Multiple sclerosis

Most Recent Events

  • 20 Dec 2017 Klogene receives SBIR grant from National Institute of Health / National Institute on Aging for Klotho protein modulators development before December 2017
  • 07 Nov 2017 Universitat Autònoma de Barcelona and Vall d"Hebron Research Institute have patent protection for Klotho gene therapy (UAB website, November 2017)
  • 31 Oct 2017 Pharmacodynamics data in Alzheimer's disease and Multiple sclerosis released by Kogenix Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top